Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

L.H. Lindholm; H. Ibsen; B. Dahlof; Dennis Johnston

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

L.H. Lindholm, H. Ibsen, B. Dahlof, Dennis Johnston

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1004-1010
Number of pages	7
Journal	The Lancet
Volume	359
Publication status	Published - Mar 2002

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{7fd23430172b45339a6092c1bd3fa411,

title = "Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol",

author = "L.H. Lindholm and H. Ibsen and B. Dahlof and Dennis Johnston",

year = "2002",

month = mar,

language = "English",

volume = "359",

pages = "1004--1010",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

AU - Lindholm, L.H.

AU - Ibsen, H.

AU - Dahlof, B.

AU - Johnston, Dennis

PY - 2002/3

Y1 - 2002/3

M3 - Article

SN - 0140-6736

VL - 359

SP - 1004

EP - 1010

JO - The Lancet

JF - The Lancet

ER -